Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Calcipotriol (ausschl. Dafo. CRE), ATC D05AX02 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Mon)

DAK-GesundheitHamburg, GermanyEUR 1 / ~EUR 11082 days leftopen

Registrieren zum Speichern Documents (1)

Opportunity Score

Confidence: 30%

Complexity: low

1082 days

Deadline

supplies

Contract

Deep Portfolio Analysis

Company fit score
Missing certificates
Eligibility blockers
Bid / No-Bid recommendation

Create account for AI analysis

AI Analysis Summary

Moderate opportunity

This is a non-exclusive discount agreement (Rabattvereinbarung) for the active ingredient Calcipotriol (excluding cream formulation, ATC D05AX02) under German social law (§ 130a Abs. 8 SGB V). The buyer DAK-Gesundheit operates an open-house model, allowing any pharmaceutical company to join at any time during the contract period (01.08.2026 - 31.07.2028, plus 12-month extension option). The procedure is not a standard tender but a transparent process to facilitate agreements. There is a single lot. Submission is via email with ongoing monthly deadlines. The estimated value is symbolic (1 EUR). No procurement documents beyond the notice were analyzed.

Strengths

Documents available

Open procedure

Low complexity

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Must be a pharmaceutical company capable of supplying Calcipotriol products (cream excluded).
Must accept contractual terms including specified discounts.
Submit offer letter, signed contract, Annexes 1 and 2 (Annex 2 in Excel) via email to [email protected].

Buyer

Name

DAK-Gesundheit

Location

Hamburg, DEU

[email protected]

Website

www.dak.de

Identifier

DE48698890

Lots (1)

#LOT-0001Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Calcipotriol (ausschl. Dafo. CRE), ATC D05AX02 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Mon)

Non-exclusive discount agreement for Calcipotriol (cream excluded). Open to all pharmaceutical companies. Contract runs 01.08.2026 - 31.07.2028 (optional +12 months). Rolling admission via email submission.

EUR 133600000DEU